DPP-4 inhibitors and severe course of illness in patients with COVID-19.

Bouhanick, Béatrice; Cracowski, Jean-Luc; Faillie, Jean-Luc

DPP-4 inhibitors and severe course of illness in patients with COVID-19.

Bouhanick, Béatrice; Cracowski, Jean-Luc; Faillie, Jean-Luc.

Bouhanick B; Service d'Hypertension Artérielle et Thérapeutique PCVM, UMR 1027, Université de Toulouse 3, CHU de Rangueil, 1, avenue J.-Poulhes, 31059 Toulouse cedex 9, France. Electronic address: duly-bouhanick.b@chu-toulouse.fr.
Cracowski JL; INSERM, HP2, Centre Régional de Pharmacovigilance et Centre d'Investigation Clinique de Grenoble, Université de Grenoble-Alpes, 38000 Grenoble, France.
Faillie JL; Département de Pharmacologie Médicale et Toxicologie, Centre Régional de Pharmacovigilance Occitanie-Est, Université de Montpellier, CHU de Montpellier, 34295 Montpellier, France.

Therapie ; 76(4): 359-360, 2021.

Article in French | MEDLINE | ID: covidwho-1031776

Subject(s)

COVID-19; Dipeptidyl-Peptidase IV Inhibitors; Humans; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Dipeptidyl-Peptidase IV Inhibitors / COVID-19 Type of study: Prognostic study Limits: Humans Language: French Journal: Therapie Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google